{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hamade DF"],"funding":["NIDDK NIH HHS","NIAID NIH HHS","NCI NIH HHS"],"pagination":["89-105"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9278541"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["198(1)"],"pubmed_abstract":["Oral administration (gavage) of a second-generation probiotic, Lactobacillus reuteri (L. reuteri), that releases interleukin-22 (LR-IL-22) at 24 h after total-body irradiation (TBI) mitigates damage to the intestine. We determined that LR-IL-22 also mitigates partial-body irradiation (PBI) and whole-abdomen irradiation (WAI). Irradiation can be an effective treatment for ovarian cancer, but its use is limited by intestinal toxicity. Strategies to mitigate toxicity are important and can revitalize this modality to treat ovarian cancer. In the present studies, we evaluated whether LR-IL-22 facilitates fractionated WAI in female C57BL/6 mice with disseminated ovarian cancer given a single fraction of either 15.75 Gy or 19.75 Gy or 4 daily fractions of 6 Gy or 6.5 Gy. Mice receiving single or "],"journal":["Radiation research"],"pubmed_title":["Lactobacillus reuteri Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer."],"pmcid":["PMC9278541"],"funding_grant_id":["U19 AI068021","R01 CA260900","K08 CA241319","T35 DK065521"],"pubmed_authors":["van Pijkeren JP","Saiful Huq M","Huang J","Espinal A","Leibowitz BJ","Mukherjee A","Wang H","Yu J","Epperly MW","Hou W","Fisher R","Greenberger JS","Patel R","Coffman L","Hamade DF","Vlad AM","Shields D"],"additional_accession":[]},"is_claimable":false,"name":"Lactobacillus reuteri Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer.","description":"Oral administration (gavage) of a second-generation probiotic, Lactobacillus reuteri (L. reuteri), that releases interleukin-22 (LR-IL-22) at 24 h after total-body irradiation (TBI) mitigates damage to the intestine. We determined that LR-IL-22 also mitigates partial-body irradiation (PBI) and whole-abdomen irradiation (WAI). Irradiation can be an effective treatment for ovarian cancer, but its use is limited by intestinal toxicity. Strategies to mitigate toxicity are important and can revitalize this modality to treat ovarian cancer. In the present studies, we evaluated whether LR-IL-22 facilitates fractionated WAI in female C57BL/6 mice with disseminated ovarian cancer given a single fraction of either 15.75 Gy or 19.75 Gy or 4 daily fractions of 6 Gy or 6.5 Gy. Mice receiving single or ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-26T07:35:55.683Z","creation":"2025-04-06T12:24:02.045Z"},"accession":"S-EPMC9278541","cross_references":{"pubmed":["35446961"],"doi":["10.1667/rade-21-00224.1","10.1667/RADE-21-00224.1"]}}